
Dr. Kaustav Talapatra is a senior Radiation Oncologist serving as Principal Director of Radiation Oncology and Lead of Academics and Clinical Research at Nanavati Max Super Speciality Hospital, Mumbai. With more than 21 years of clinical experience, he specialises in advanced radiation oncology, stereotactic radiosurgery and precision-based cancer treatment.
He completed his MBBS from St. John's Medical College, Bengaluru, followed by an MD from Christian Medical College, Vellore. His advanced professional training includes exposure to leading international cancer and radiosurgery institutions, including Champalimaud Centre for the Unknown, Portugal, Humanitas, Milan, and University Hospital Zurich.
His clinical expertise includes cranial and extracranial radiosurgery, Stereotactic Body Radiation Therapy (SBRT), high-precision radiation treatment and advanced techniques for cancers involving the gastrointestinal tract, lungs, head and neck. He has also played an important role in developing specialised radiosurgery infrastructure and clinical training programmes.
Before joining Nanavati Max, Dr. Talapatra held senior positions at Tata Memorial Hospital and Kokilaben Dhirubhai Ambani Hospital, Mumbai, and served as National Head of Radiation Oncology at Reliance Cancer Centres. He has contributed to medical research through numerous publications and academic presentations and previously directed the Varian International Clinical School for Stereotactic Radiosurgery.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Kaustav Talapatra for Hematology & BMT treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Hematology & BMT in India.
Dr. Kaustav Talapatra regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Kaustav Talapatra holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in Hematology & BMT.
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
AML, CML, CLL, ALL, Hodgkin & Non-Hodgkin Lymphoma, Multiple Myeloma — treated with chemotherapy, targeted therapy & BMT.
Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders.
Cutting-edge immunotherapy using genetically modified T-cells for blood cancers that have relapsed after standard treatments.
Curative BMT for thalassemia major and sickle cell anemia in children and adults. Low-cost programs available across India.
Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.
HSCT (Hematopoietic Stem Cell Transplant) for aggressive Multiple Sclerosis — a disease-modifying treatment available in India.
Expert care for childhood leukemia, thalassemia, ITP, and inherited bone marrow failure syndromes.
Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with modern protocols.
Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and coagulopathies.
The most complex and potentially curative form of BMT where stem cells come from a matched donor. Used for leukemia, aplastic anemia, and inherited blood disorders.
Patient's own stem cells are harvested and reinfused after high-dose chemotherapy. Used for multiple myeloma and relapsed lymphomas.
Revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.
The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation.
Personalised chemotherapy and next-generation targeted agents for lymphoma, leukaemia, and related disorders.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.